100
NPS Score
VS
Karyopharm Therapeutics Claimed Company
- This companyis accepting feedback from verified employeesEMPLOYEE
PARTICIPANTS - 90
- TOTAL
RATINGS
Sarepta Therapeutics Claimed Company
- EMPLOYEE
PARTICIPANTS - 34
- TOTAL
RATINGS
Karyopharm Therapeutics vs Sarepta Therapeutics
Compare Karyopharm Therapeutics versus Sarepta Therapeutics for CEO Rating, Overall Culture Score, Brand Ranking, and other ratings. Results were generated by 90 employees and customers of Karyopharm Therapeutics and 34 employees and customers of Sarepta Therapeutics.
Karyopharm Therapeutics
Karyopharm Therapeutics's brand is ranked #- in the list of Global Top 1000 Brands, as rated by customers of Karyopharm Therapeutics. Their current market cap is $753.30M.
Sarepta Therapeutics
Sarepta Therapeutics's brand is ranked #- in the list of Global Top 1000 Brands, as rated by customers of Sarepta Therapeutics. Their current market cap is $11.66B.
5/5
Product Quality
3.7/5
5/5
Pricing
3.7/5
5/5
Customer Service
5/5
| 100% | Promoters |
|---|---|
| 0% | Passive |
| 0% | Detractors |
Net Promoter Score
Winner by 109
-9
NPS Score
| 36% | Promoters |
|---|---|
| 19% | Passive |
| 45% | Detractors |
See how Karyopharm Therapeutics compares to its competitors
Working at Karyopharm Therapeutics vs Working at Sarepta Therapeutics
82 / 100
CEO Rating
Winner by 3%
79 / 100
CEO Rating
Karyopharm Therapeutics
Karyopharm Therapeutics doesn't have enough ratings to calculate the Team Culture Ratings.
Know someone that works there? Invite them to rate their experience.
Sarepta Therapeutics
Employees at Sarepta Therapeutics rate their CEO, Douglas Ingram, 79/100. This score is 3% lower than the scores of Karyopharm Therapeutics' CEO, Richard Paulson.